ANANDAMIDES - TOLERANCE AND CROSS-TOLERANCE TO DELTA(9)-TETRAHYDROCANNABINOL

被引:52
作者
FRIDE, E
机构
[1] Department of Natural Products, Hebrew University Medical Faculty, Jerusalem, 91120
关键词
TOLERANCE; ANANDAMIDE; DELTA(9)-THC; CANNABINOID; CANNABINOID RECEPTOR; G(I) PROTEIN; G(S) PROTEIN;
D O I
10.1016/0006-8993(95)00790-W
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In this study we examined whether tolerance develops to chronic exposure to anandamides [20:4, n-6 (ANA) and 20:3, n-6 (HLEA)] two of the recently discovered endogenous cannabinoid receptor ligands in brain. Tolerance to ANA and cross-tolerance to Delta(9)-tetrahydrocannabinol (Delta(9)-THC) was examined in female Sabra or C57BL/6 mice which had received daily injections (i.p.) of low (0.001-1 mg/kg) or high doses (20 mg/kg) of ANA or HLEA for 2 weeks. Twenty four h after the last injection, the mice were challenged with 20 mg/kg ANA or Delta(9)-THC. Animals were subjected to a series of tests frequently used to assess cannabinoid-induced effects. The results indicated that the high dose, but not the low doses of anandamides produced tolerance to ANA and cross-tolerance to Delta(9)-THC for motor activity in an open field, catalepsy on a ring, hypothermia and analgesia on a hot plate. One week after the last ANA treatment, tolerance was not present anymore. No tolerance to ANA was observed for reduced defecation in the open field, a measure of intestinal hypomotility. This phenomenon may possibly be attributed to a difference between activities produced through different types of cannabinoid receptors.
引用
收藏
页码:83 / 90
页数:8
相关论文
共 48 条
[11]   ANANDAMIDE, AN ENDOGENOUS LIGAND OF THE CANNABINOID RECEPTOR, INDUCES HYPOMOTILITY AND HYPOTHERMIA IN-VIVO IN RODENTS [J].
CRAWLEY, JN ;
CORWIN, RL ;
ROBINSON, JK ;
FELDER, CC ;
DEVANE, WA ;
AXELROD, J .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1993, 46 (04) :967-972
[12]  
DAVIS WM, 1972, RES COMMUN CHEM PATH, V3, P29
[13]   DOWN-REGULATION OF RAT-BRAIN CANNABINOID BINDING-SITES AFTER CHRONIC DELTA-9-TETRAHYDROCANNABINOL TREATMENT [J].
DEFONSECA, FR ;
GORRITI, MA ;
FERNANDEZRUIZ, JJ ;
PALOMO, T ;
RAMOS, JA .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1994, 47 (01) :33-40
[14]  
DEVANE WA, 1988, MOL PHARMACOL, V34, P605
[15]   ISOLATION AND STRUCTURE OF A BRAIN CONSTITUENT THAT BINDS TO THE CANNABINOID RECEPTOR [J].
DEVANE, WA ;
HANUS, L ;
BREUER, A ;
PERTWEE, RG ;
STEVENSON, LA ;
GRIFFIN, G ;
GIBSON, D ;
MANDELBAUM, A ;
ETINGER, A ;
MECHOULAM, R .
SCIENCE, 1992, 258 (5090) :1946-1949
[16]  
DEWEY WL, 1986, PHARMACOL REV, V38, P151
[17]  
DILL JA, 1988, J PHARMACOL EXP THER, V244, P1157
[18]  
EDDY NB, 1950, J PHARMACOL EXP THER, V98, P121
[19]   ANANDAMIDE, AN ENDOGENOUS CANNABIMIMETIC EICOSANOID, BINDS TO THE CLONED HUMAN CANNABINOID RECEPTOR AND STIMULATES RECEPTOR-MEDIATED SIGNAL-TRANSDUCTION [J].
FELDER, CC ;
BRILEY, EM ;
AXELROD, J ;
SIMPSON, JT ;
MACKIE, K ;
DEVANE, WA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (16) :7656-7660